– USA, NY – Misonix, Inc. (Nasdaq: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced the appointment of Patrick Beyer to its Board as an Independent Director, on May 12, 2021.
“Pat is a highly respected, purpose-driven leader who has a proven, long-term track record of success throughout his career in the healthcare industry,” said CEO, Stavros Vizirgianakis.
He added: “Pat has been an integral member of ConMed’s executive team and his leadership expertise in strategy, business development, operations, and finance will be valuable to Misonix in supporting our goals for sustainable revenue growth and profitability, as well as the enhancement of long-term shareholder value. We are very excited to have Pat join our Board and look forward to his contributions as we continue to strengthen and grow our business by leveraging our cutting-edge ultrasonic technology and regenerative products to deliver best-in-class solutions with demonstrated clinical benefits that improve patient outcomes.”
About Pat Beyer
Mr. Beyer is currently President of International and Global Orthopedics for ConMed Corporation, a publicly held medical technology company, a position in which he has served since October 2020. Mr. Beyer previously served as President of ConMed International. Prior, Mr. Beyer served as CEO of ICNet, a privately held infectious control software company from 2010 to 2014 when the company was sold. Before this, Mr. Beyer spent 21 years at Stryker Corporation where he led Stryker Europe from 2005 to 2009; Stryker UK, South Africa, and Ireland from 2002 to 2005 and Stryker Medical from 1999 to 2002.
Mr. Beyer commented: “I am very excited to join the Misonix Board of Directors and be part of a growing company with leading ultrasonic products and procedural solutions powered by proprietary technology and backed by robust clinical data. I look forward to sharing my experience and knowledge with the Board and management team to advance the Company’s strategic growth objectives and maximize the many significant opportunities in front of Misonix to disrupt large markets and expand share.”
Mr. Beyer graduated from Kalamazoo College with a BA in Economics, obtained his MBA in Finance from Western Michigan, and attended Harvard Business School’s Advanced Management Program.
About Misonix, Inc.
Misonix, Inc. is a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative tissue products. Its surgical team markets and sells BoneScalpel and SonaStar, which facilitate precise bone sculpting and removal of soft and hard tumors and tissue, primarily in the areas of neurosurgery, orthopedic, plastic, and maxillo-facial surgery. The Company’s wound team markets and sells TheraSkin, Therion, TheraGenesis, and SonicOne to debride, treat and heal chronic and traumatic wounds in inpatient, outpatient, and physician office sites of service. At Misonix, Better Matters! That is why throughout the Company’s history, Misonix has maintained its commitment to medical technology innovation and the development of products that radically improve outcomes for patients.
For more information: https://www.misonix.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.